(2014/04) Vitamin A and risk of bladder cancer: a meta-analysis of epidemiological studies.

(2008/11) Plasma vitamins E and A and risk of bladder cancer: a case-control analysis.

(2004/04) The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder.

(2003/10) Serum vitamins and the subsequent risk of bladder cancer.

(2002/10) Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study.

(2001/12) Retinoids in the prevention of bladder cancer.

(1995/01) Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland.

(1994/01) Megadose vitamins in bladder cancer: a double-blind clinical trial.

(1995/01) Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study

(1994/01) Megadose vitamins in bladder cancer: a double-blind clinical trial.

(2004/06) Carotenoids/vitamin C and smoking-related bladder cancer.

(2002/12) Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women.

(1994/01) Megadose vitamins in bladder cancer: a double-blind clinical trial.

(2018/10) Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder.

(2016/05) Comparative efficacy of vitamin D status in reducing the risk of bladder cancer: A systematic review and network meta-analysis.

(2015/05) Vitamin D Deficiency and Increased Risk of Bladder Carcinoma: A Meta-Analysis.

(2015/04) Association of vitamin C, vitamin D, vitamin E and risk of bladder cancer: a dose-response meta-analysis.

(2015/03) Impact of serum vitamin D level on risk of bladder cancer: a systemic review and meta-analysis.

(2013/03)Relationship of vitamin D monitoring and status to bladder cancer survival in veterans.

(2015/04) Association of vitamin C, vitamin D, vitamin E and risk of bladder cancer: a dose-response meta-analysis.

(2014/11) Vitamin C and E intake and risk of bladder cancer: a meta-analysis of observational studies.

(2014/06) Effect of potassium magnesium citrate and vitamin B-6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis.

(2012/10) High dietary magnesium intake decreases hyperoxaluria in patients with nephrolithiasis

(2005/06) Magnesium therapy for nephrolithiasis.

(2005/03) Importance of magnesium in absorption and excretion of oxalate.

(2004/01) Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.

(1994/03) Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers

(1992/03) Physicochemical action of potassium-magnesium citrate in nephrolithiasis.

(1990/02) Effect of magnesium citrate and magnesium oxide on the crystallization of calcium salts in urine: changes produced by food-magnesium interaction.

(2014/06) Effect of potassium magnesium citrate and vitamin B-6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis.

(2009/03) Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation

(2004/01) Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.

(1997/12) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis

(1993/12) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium

(1992/03) Physicochemical action of potassium-magnesium citrate in nephrolithiasis

(1991/02) Contrasting effects of various potassium salts on renal citrate excretion.

(2014/06) Effect of potassium magnesium citrate and vitamin B-6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis.

(2011/05) Pyridoxine and Dietary Counseling for the Management of Idiopathic Hyperoxaluria in Stone-forming Patients.

(2005/02) Effect of pyridoxine (vitamin B6) supplementation on calciuria and oxaluria levels of some normal healthy persons and urinary stone patients

(1999/04) Intake of vitamins B6 and C and the risk of kidney stones in women.

(1996/06) A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men

(1994/12) Effect of combined supplementation of magnesium oxide and pyridoxine in calcium oxalate stone formers

(2020/07) A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency.

(2000/05) Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up.

(2000/01) Beta-sitosterols for benign prostatic hyperplasia.

(1999/06) Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.

(1997/09) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.

(1995/06) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.

(2017/01) Race and BMI modify associations of calcium and vitamin D intake with prostate cancer.

(2015/01) Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study.

(2015/01) Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies.

(2021/08) Curcumin for the Treatment of Prostate Diseases: A Systematic Review of Controlled Clinical Trials.

(2020/11) Curcumin against Prostate Cancer: Current Evidence.

(2019/05) A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation.

(2019/02) Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy.

(2018/06) Effect on prostatic specific antigen by a short time treatment with a Curcuma extract: A real life experience and implications for prostate biopsy.

(2016/01) Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study.

(2010/07) Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen.

(2017/12) Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis.

(2017/06) Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.

(2015/11) A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality.

(2009/03) Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.

(2007/09) Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study.

(2006/03) Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States).

(2005/11) Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia.

(2004/09) Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer

(2003/11) Prostate Carcinogenesis in N-methyl-N-nitrosourea(NMU)- Testosterone-Treated Rats Fed Tomato Powder, Lycopene, or Energy-Restricted Diets

(2003/09) A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer.

(2002/11) Effects of lycopene supplementation in patients with localized prostate cancer.

(2002/11) Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis.

(2002/03) A prospective study of tomato products, lycopene, and prostate cancer risk

(2001/08) Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.

(1995/12) Intake of carotenoids and retinol in relation to risk of prostate cancer.

(2016/07) Omega-3 Fatty Acid Consumption and Prostate Cancer: A Review of Exposure Measures and Results of Epidemiological Studies.

(2014/01) Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy.

(2013/08) Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

(2011/12) Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy.

(2007/01) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism.

(2007/01) Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men.

(2006/03) Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs.

(2006/03) Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States).

(2004/12) Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma.

(2004/07) Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer

(2017/03) The Efficacy of an Association of Palmitoylethanolamide and Alpha-Lipoic Acid in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Randomized Clinical Trial.

(2011/08) Quercetin for chronic prostatitis/chronic pelvic pain syndrome.

(1999/12) Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial.

(2019/01)The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids.

(2017/04) The role of flower pollen extract in managing patients affected by chronic prostatitis/chronic pelvic pain syndrome: a comprehensive analysis of all published clinical trials.

(2014/01) Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome.

(2013/04) Effects of pollen extract in association with vitamins (DEPROX 500®) for pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome: results from a pilot study.

(2011/08) Pollen extract for chronic prostatitis-chronic pelvic pain syndrome.

(2009/09) A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, prospective, double-blind, placebo-controlled phase 3 study.

(2006/01) Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study.

(2020/07) A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency.

(2018/04) Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.

(2015/12) Effects of hexanic extract of serenoa repens (permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.

(2015/07) Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study.

(2013/12) Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?

(2013/08) The results of the 10-year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia

(2013/04) Safety and toxicity of saw palmetto in the CAMUS trial.

(2013/02) Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial.

(2012/09) Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.

(2012/06) Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation.

(2012/02) The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial.

(2011/09) Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.

(2011/03) Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia.

(2010/09) Serenoa repens (Permixon®) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia.

(2007/03) A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.

(2005/03) Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.

(2004/06) Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.

(2002/06) Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study

(1996/10) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.

(2017/02) Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis.

(2016/07) Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies.

(2015/11) A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality.

(2015/10) Cancer Chemoprevention Research with Selenium in the Post-SELECT Era: Promises and Challenges.

(2013/04) Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT).

(2012/07) Selenium and prostate cancer: systematic review and meta-analysis.

(2009/08) Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer

(2009/01) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial

(2004/05) A prospective study of plasma selenium levels and prostate cancer risk.

(2003/05) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial.

(2003/02) Serum selenium and risk of prostate cancer in U.S. blacks and whites.

(2002/11) Influence of Selenium-enriched Yeast Supplementation on Biomarkers of Oxidative Damage and Hormone Status in Healthy Adult Males: A Clinical Pilot Study.

(1998/05) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial.

(2019/01) Soy Isoflavones Protect Normal Tissues While Enhancing Radiation Responses.

(2018/01) Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis.

(2016/07) Is phytoestrogen intake associated with decreased risk of prostate cancer? A systematic review of epidemiological studies based on 17,546 cases.

(2015/11)Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.

(2015/11) A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality.

(2011/07) Soy isoflavones sensitize cancer cells to radiotherapy

(2010/10) Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer.

(2010/07) Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen.

(2010/06) A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer.

(2010/01) Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells.

(2008/05) Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.

(2007/08) Dietary isoflavones may protect against prostate cancer in Japanese men.

(2007/06) Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model.

(2006/06) Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men.

(2004/05) The specific role of isoflavones in reducing prostate cancer risk.

(2003/11) Soy Isoflavones in the Treatment of Prostate Cancer

(2002/10) Genestein and vitamin D synergistically inhibit human prostatic epithelial cell growth.

(2001/02) Genetein Potentiates the Radiation Effect on Prostate Carcinoma Cells

(1998/12) Does high soy milk intake reduce prostate cancer incidence?

(2018/10) Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis.

(2018/10) Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder.

(2017/07) Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.

(2017/03) Low vitamin D status is associated with inflammation in patients with prostate cancer.

(2017/01) Race and BMI modify associations of calcium and vitamin D intake with prostate cancer.

(2016/12) Association between Serum 25-Hydroxy-Vitamin D and Aggressive Prostate Cancer in African American Men.

(2016/04) Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.

(2016/04) Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival.

(2016/01) A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk.

(2016/01) Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case-control study.

(2014/08) Serum 25-Hydroxyvitamin D concenrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

(2014/01) Vitamin D and prostate cancer survival in veterans.

(2012/05) Vitamin d-related genetic variation, plasma vitamin d, and risk of lethal prostate cancer: a prospective nested case-control study.

(2012/04) Vitamin D3 Supplementation at 4000 International Units Per Day for One Year Results in a Decrease of Positive Cores at Repeat Biopsy in Subjects with Low-Risk Prostate Cancer under Active Surveillance.

(2011/10) Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade.

(2011/10) Vitamin D deficiency in the urological population: a single center analysis

(2011/09) Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study

(2009/01) Association between serum 25(OH)D and death from prostate cancer

(2006/09) Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer.

(2005/01) Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.

(2004/01) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk

(2002/03) An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation.

(2015/11) Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.

(2014/09) Blood α-tocopherol, γ-tocopherol levels and risk of prostate cancer: a meta-analysis of prospective studies.

(2014/05) Genetic variants reflecting higher vitamin e status in men are associated with reduced risk of prostate cancer.

(2012/04) Does Vitamin E Prevent or Promote Cancer?

(2011/10) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial

(2009/01) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial

(2008/02) Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort.

(2005/03) Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study.

(2003/07) Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation

(2001/12) Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention.

(2000/12) Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer.

(1999/10) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States.

(1998/03) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial.

(2021/06) Non-antibiotic interventions for prevention of urinary tract infections in children: a systematic review and meta-analysis of randomized controlled trials.

(2019/05) Recurrent Uncomplicated Urinary Tract Infections In Women: AUA/CUA/SUFU Guideline.

(2018/10) Cranberry Standardized Capsules May Prevent Recurrences of Urinary Tract Infections in Children.

(2017/12) Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis.

(2017/09) Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials.

(2016/11) Effect of Cranberry Capsules on Bacteriuria Plus Pyuria Among Older Women in Nursing Homes: A Randomized Clinical Trial.

(2016/09) Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study.

(2016/06) Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection episodes in women with a recent history of urinary tract infection.

(2015/12) Cranberry Products for the Prophylaxis of Urinary Tract Infections in Pediatric Patients.

(2015/08) Cranberry juice capsules and urinary tract infection after surgery: results of a randomized trial.

(2015/01) Cranberry supplementation in the prevention of non-severe lower urinary tract infections: a pilot study.

(2014/01) Effectiveness of cranberry capsules to prevent urinary tract infections in vulnerable older persons: a double-blind randomized placebo-controlled trial in long-term care facilities.

(2012/10) Cranberries for preventing urinary tract infections.

(2012/07) Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials.

(2011/06) Inhibition of adherence of multi-drug resistant E. coli by proanthocyanidin

(2011/01) Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial

(2009/07) Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration

(2009/02) Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women

(2008/10) Daily cranberry juice for the prevention of asymptomatic bacteriuria in pregnancy: a randomized, controlled pilot study.

(2007/06) Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells.

(2007/04) Biosafety, antioxidant status, and metabolites in urine after consumption of dried cranberry juice in healthy women: a pilot double-blind placebo-controlled trial.

(2006/02) Reduction of Escherichia coli adherence to uroepithelial bladder cells after consumption of cranberry juice: a double-blind randomized placebo-controlled cross-over trial.

(2005/11) Inhibition of uropathogenic Escherichia coli by cranberry juice: a new antiadherence assay.

(2005/09) A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity.

(2005/05) Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial.

(2002/06) A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women.

(2001/06) Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women.

(1998/10) Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries.

(2021/04) Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives.

(2016/07) D-mannose: a promising support for acute urinary tract infections in women. A pilot study.

(2014/01) Oral D-mannose in recurrent urinary tract infections in women: a pilot study.

(2014/02) D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial.

(2013/10) Use of d‐mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women.